🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors NCT04977453Phase 1, Phase 213 sites📍 New York📍 New York📍 Huntersville GI Innovation, Inc. · Tests: GI-101, Pembrolizumab (KEYTRUDA®), Lenvatinib, GI-101A A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies NCT05473156Phase 1, Phase 21 site📍 Taipei AP Biosciences Inc. · Tests: AP203, AP203 Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study NCT07405086Phase 41 site📍 Portland OHSU Knight Cancer Institute · Tests: Biospecimen Collection, Immune Checkpoint Inhibitor Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors NCT04777994Phase 130 sites📍 Tucson📍 New Haven📍 Baltimore Calico Life Sciences LLC · Tests: ABBV-CLS-484, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI), Programmed Cell Deat… Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations NCT06772623Phase 1, Phase 2126 sites📍 Phoenix📍 Fullerton📍 Oxnard AbbVie · Tests: Telisotuzumab Adizutecan, Budigalimab, Pembrolizumab, Pembrolizumab, Carboplatin A Study of IDP-001 in Advanced or Metastatic Solid Tumors NCT07602842Phase 1, Phase 26 sites📍 Los Angeles📍 Sarasota📍 Indianapolis InduPro, Inc. · Tests: IDP-001 Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations NCT07336732Phase 21 site📍 Guangzhou Avistone Biotechnology Co., Ltd. · Tests: PLB1004 A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer NCT07155187Phase 2, Phase 3117 sites📍 Springdale📍 Duarte📍 Irvine AbbVie · Tests: Telisotuzumab Adizutecan, Standard of Care, Osimertinib A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC NCT07264816Phase 21 site📍 Wuhan Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-M07D1, Pembrolizumab A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) NCT06692738Phase 3328 sites📍 Tucson📍 Springdale📍 Anaheim AstraZeneca · Tests: Rilvegostomig, Pembrolizumab, Carboplatin, Paclitaxel, Nab-paclitaxel A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors NCT07229313Phase 17 sites📍 Santa Monica📍 New Have📍 Camperdown Kivu Bioscience Inc. · Tests: KIVU-107 Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer NCT07416994Phase 32 sites📍 Shanghai📍 Hangzhou MediLink Therapeutics (Suzhou) Co., Ltd. · Tests: YL202, Docetaxel A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies NCT07613723Phase 12 sites📍 London📍 Manchester Zelluna Immunotherapy AS · Tests: ZI-MA4-1 (TCR-NK cells), Cyclophosphamide, Fludarabine A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) NCT06875310Phase 3351 sites📍 Birmingham📍 Springdale📍 Fullerton Mirati Therapeutics Inc. · Tests: Adagrasib, Pembrolizumab, Carboplatin, Pemetrexed, Placebo Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer NCT06899126Phase 3246 sites📍 Anchorage📍 Fountain Valley📍 Los Angeles Daiichi Sankyo · Tests: Trastuzumab Deruxtecan, pembrolizumab, Pemetrexed, Platinum Chemotherapy A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors NCT05592626Phase 1, Phase 219 sites📍 Sacramento📍 Celebration📍 Miami Marengo Therapeutics, Inc. · Tests: STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere) Study of XB010 in Subjects With Solid Tumors NCT06545331Phase 120 sites📍 Irvine📍 Los Angeles📍 Washington D.C. Exelixis · Tests: XB010, Pembrolizumab Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors NCT07030257Phase 1, Phase 213 sites📍 Denver📍 Orlando📍 Grand Rapids Tasca Therapeutics · Tests: CP-383 A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors NCT07887971Phase 11 site📍 Miami Aktis Oncology, Inc. · Tests: [225Ac]Ac-AKY-2519 (therapeutic), [64Cu]Cu-AKY-2519 (imaging) Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC NCT06332755Phase 11 site📍 Fairfax LG Chem · Tests: Phase 1a: LB-LR1109, Phase 1b: LB-LR1109 and Atezolizumab A Study of SH009 Injection in Patients With Advanced Solid Tumors. NCT07390838Phase 11 site📍 Shanghai Nanjing Sanhome Pharmaceutical, Co., Ltd. · Tests: SH009 Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) NCT04198766Phase 1, Phase 242 sites📍 Duarte📍 Glendale📍 Los Angeles Inhibrx Biosciences, Inc · Tests: INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg, Carboplatin AUC-5, Carboplati… A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors NCT06561685Phase 133 sites📍 Santa Monica📍 Aurora📍 Denver Eli Lilly and Company · Tests: LY4050784, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer NCT07222566Phase 3484 sites📍 Bullhead City📍 Chandler📍 Gilbert Pfizer · Tests: PF-08634404, Pembrolizumab, Chemotherapy Regimen 1, Chemotherapy Regimen 2 A Study of NX-1607 in Adults With Advanced Malignancies NCT05107674Phase 117 sites📍 Duarte📍 Los Angeles📍 San Francisco Nurix Therapeutics, Inc. · Tests: NX-1607, Paclitaxel Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors NCT06975410Phase 1, Phase 24 sites📍 Seoul📍 Seoul📍 Seoul Yuhan Corporation · Tests: YH32364 A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC NCT06627647Phase 3300 sites📍 Mobile📍 Chandler📍 Phoenix AstraZeneca · Tests: Rilvegostomig, Pembrolizumab, Carboplatin, Cisplatin, Pemetrexed Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations NCT07291037Phase 3206 sites📍 Chandler📍 Gilbert📍 Goodyear AstraZeneca · Tests: Datopotamab deruxtecan (Dato-DXd), Docetaxel A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations NCT06735391Phase 31 site📍 Guangzhou Shanghai JMT-Bio Inc. · Tests: JMT101, Osimertinib First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors NCT07284186Phase 110 sites📍 Scottsdale📍 Duarte📍 Orange Plexium, Inc. · Tests: PLX-61639
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy